分组1 - Embecta Corp. reported quarterly earnings of $0.65 per share, exceeding the Zacks Consensus Estimate of $0.45 per share, and showing an increase from $0.61 per share a year ago, resulting in an earnings surprise of 44.44% [1] - The company achieved revenues of $261.9 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 2.02%, although this represents a decline from year-ago revenues of $277.3 million [2] - Over the last four quarters, Embecta Corp. has consistently surpassed consensus EPS and revenue estimates [2] 分组2 - The stock has underperformed, losing about 11.9% since the beginning of the year, while the S&P 500 has gained 3.1% [3] - The current consensus EPS estimate for the upcoming quarter is $0.72 on revenues of $272.06 million, and for the current fiscal year, it is $2.84 on revenues of $1.11 billion [7] - The Medical Services industry, to which Embecta Corp. belongs, is currently ranked in the bottom 34% of over 250 Zacks industries, indicating potential challenges ahead [8]

Forward-Looking Statements Earnings Conference Call Fiscal Q1 2025 February 6, 2025 Safe Harbor Statement Regarding Forward-Looking Statements Today's topics: Strategic Priorities Dev Kurdikar Chief Executive Officer Jake Elguicze Chief Financial Officer Guidance Q&A Pravesh Khandelwal This presentation contains express or implied "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995 and other securities laws. These forward-looking statements concern ou ...

Financial Performance - Revenues for Q1 FY2025 were $261.9 million, a decrease of 5.6% from $277.3 million in Q1 FY2024[4] - U.S. revenues decreased by 4.6% to $141.7 million, while international revenues decreased by 6.6% to $120.2 million[7] - Gross profit was $157.1 million with a margin of 60.0%, down from $185.9 million and 67.0% in the prior year[4] - Adjusted net income was $38.3 million, or $0.65 per diluted share, compared to $35.3 million, or $0.61 per diluted share in the prior year[4] - Reported revenues for the three months ended December 31, 2024, were $261.9 million, down from $277.3 million in the same period of 2023, indicating a decrease of about 5.2%[24] - GAAP net income for the three months ended December 31, 2024, was $0, compared to $20.1 million for the same period in 2023, reflecting a significant decline[21] - Adjusted EBITDA for Q1 FY2025 was $97.3 million, with a margin of 37.2%, compared to $90.4 million and 32.6% in the prior year[4] - Adjusted EBITDA for the three months ended December 31, 2024, was $97.3 million, an increase from $90.4 million in the same period of 2023, resulting in an adjusted EBITDA margin of 37.2% compared to 32.6%[24] - GAAP Operating Income for Q4 2024 was $28.7 million, down from $45.5 million in Q4 2023, resulting in a margin decrease from 16.4% to 11.0%[30] - Adjusted Operating Income increased to $80.5 million in Q4 2024, compared to $77.5 million in Q4 2023, with an improved margin of 30.7% versus 27.9%[30] - Adjusted Net Income rose to $38.3 million in Q4 2024, up from $35.3 million in Q4 2023, with Adjusted Net Income per Diluted share increasing from $0.61 to $0.65[30] Cash and Debt Management - The company had approximately $216.7 million in cash and equivalents and $1.569 billion in debt principal outstanding as of December 31, 2024[12] - Cash and equivalents decreased from $267.5 million as of September 30, 2024, to $210.0 million as of December 31, 2024, a reduction of approximately 21.5%[19] - Closing cash and equivalents and restricted cash were $216.7 million as of December 31, 2024, down from $298.7 million as of December 31, 2023[21] - Payments on long-term debt amounted to $32.4 million for the three months ended December 31, 2024, compared to $2.4 million in the same period of 2023[21] Restructuring and Strategic Initiatives - The restructuring plan related to the discontinuation of the insulin patch pump program is on track to be completed by the end of the first half of FY2025[5] - The brand transition program is progressing as planned, with the U.S. and Canada expected to transition in the second half of FY2025[5] - Future guidance includes plans for market expansion and strengthening the core business, alongside a restructuring plan related to the insulin patch pump program[32] - The company is actively pursuing strategic partnerships and acquisitions to enhance its product portfolio and market presence[32] Asset Management - Total assets decreased from $1,285.3 million as of September 30, 2024, to $1,149.5 million as of December 31, 2024, representing a decline of approximately 10.6%[19] - Total current liabilities decreased from $374.0 million as of September 30, 2024, to $298.2 million as of December 31, 2024, a decline of about 20.3%[19] - The accumulated deficit increased from $(498.6) million as of September 30, 2024, to $(507.9) million as of December 31, 2024[19] Employee and Operational Insights - The company has approximately 2,000 employees globally, focusing on innovative solutions in diabetes care[32] - Costs associated with the discontinued patch pump program amounted to $39.6 million in Q4 2024, with significant expenses recorded in R&D and other operating costs[30] Dividend Announcement - The company announced a quarterly cash dividend of $0.15 per share, payable on March 14, 2025[13] Tax and Shareholder Information - The non-GAAP effective tax rate for Q4 2024 was 25.0%, a slight decrease from 26.0% in Q4 2023[31] - Basic weighted average shares outstanding increased to 57,952 thousand in Q4 2024 from 57,486 thousand in Q4 2023[30]

Core Viewpoint - Embecta Corp reported a decline in revenues for the first quarter of fiscal year 2025, driven by unfavorable changes in volume and foreign currency translation, while also updating its financial guidance for the year [2][10][9]. Financial Highlights - Total revenues for the three months ended December 31, 2024, were $261.9 million, a decrease of 5.6% from $277.3 million in the same period of 2023 [7][9]. - U.S. revenues decreased by 4.6% on both reported and adjusted constant currency bases, while international revenues fell by 6.6% reported and 5.1% adjusted [6][7]. - Gross profit was $157.1 million with a margin of 60.0%, down from $185.9 million and 67.0% in the prior year [7][16]. - Adjusted net income was $38.3 million, or $0.65 per diluted share, compared to $35.3 million, or $0.61 per diluted share in the prior year [7][29]. Strategic Highlights - The company is on track to complete its restructuring plan related to the discontinuation of the insulin patch pump program by the end of the first half of fiscal year 2025 [2][7]. - A brand transition plan is set to launch in the second half of the fiscal year, starting in the U.S. and Canada [2][7]. - Progress is being made on GLP-1 initiatives to enhance patient access to pen needles for GLP-1 pen injectors [2][7]. Updated Financial Guidance - For fiscal year 2025, Embecta expects reported revenues to be between $1,075 million and $1,092 million, down from previous guidance of $1,093 million to $1,110 million [10]. - Adjusted constant currency revenue growth is anticipated to be between (2.5)% and (1.0)% [10]. - Adjusted gross margin is expected to remain between 63.25% and 64.25% [10]. Balance Sheet and Liquidity - As of December 31, 2024, the company had approximately $216.7 million in cash and equivalents, with total debt principal outstanding at $1.569 billion [11][19]. - The company declared a quarterly cash dividend of $0.15 per share, payable on March 14, 2025 [12][19].

PARSIPPANY, N.J., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (NASDAQ:EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host a conference call to discuss its fiscal first quarter 2025 financial results, provide an operational update, and host a question and answer session, at 8:00 a.m. Eastern Time (ET) on Thursday, February 6, 2025. Those who would like to participate may access the live webcast here, or access the teleconference here. The live webcast c ...

Stocks hitting their 52-week high and delivering consistent performance offer attractive opportunities to investors while building a portfolio. This is because stocks near that level are perceived to be winners. However, stocks touching a new 52-week high are often predisposed to profit-taking, resulting in pullbacks and trend reversals. Moreover, given the high price, investors often wonder if the stock is overpriced. While the speculations are not absolutely baseless, all stocks hitting a 52-week high are ...

PARSIPPANY, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- Embecta Corp. (embecta) (Nasdaq: EMBC) today announced that management will present at the J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 15, 2025 at 7:30 a.m. PT / 10:30 a.m. ET. Audio webcasts of the presentations will be accessible under the “News & Events” section of the Company's investor relations website at investors.embecta.com. About embecta embecta is a global diabetes care company that is leveraging its nearly 100-year ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _ to _ Commission file number 001-41186 EMBECTA CORP. (Exact name of registrant as specified in its charter) Delaware 87-1583942 (State or other jurisdiction of incorporatio ...

Robert F. Abbott has been investing his family’s accounts since 1995, and in 2010 added options, mainly covered calls and collars with long stocks. He is a freelance writer, and his projects include a website that provides information for new and intermediate-level mutual fund investors. A resident of Airdrie, Alberta, Canada, Robert has earned Bachelor of Arts and Master of Business Administration (MBA) degrees.Analyst’s Disclosure: I/we have no stock, option or similar derivative position in any of the co ...

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today:Embecta Corp. (EMBC) : This medical device company has seen the Zacks Consensus Estimate for its current year earnings increasing 14.9% over the last 60 days.Toast, Inc. (TOST) : This cloud-based digital technology platform provider has seen the Zacks Consensus Estimate for its current year earnings increasing 120% over the last 60 days.monday.com Ltd. (MNDY) : This software development company has seen the Zacks Consensus Estimate for ...